The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

Register now for the Feb 27th AIRR Community Seminar Series

by

Registration for the February 27th (4:00 PM – 5:30 PM CET) AIRR-C Seminar Series session is open. Following the usual format of the series, an established and an early career scientist will discuss their AIRR-seq related research.

Steven E. Bosinger, Emory University, USA will present “A Broad Survey and Functional Analysis of Immunoglobulin Loci Variation in Rhesus Macaques.” Next, Maria F. Abbate, École Normale Supérieure, France will present “Computational detection of antigen specific BCRs for antibody discovery.”

REGISTER NOW!

Visit the AIRR Community Seminar Series website to learn more about this monthly series and access the recordings of past sessions.

Season 3 of On AIRR is here!

by

We’re thrilled to announce the launch of Season 3 of On AIRR, the official podcast of the AIRR Community. This season kicks off with an insightful discussion featuring Dr. Thierry Mora and Dr. Aleksandra Walczak —  co-leaders of the Statistical Biophysics Group at Laboratoire de physique de l’ENS (LPENS) in Paris, France.

Dr. Mora and Dr. Walczak, physicists by training, have been pioneers in applying biophysics, neuroscience, and information theory methods to the analysis of the adaptive immune system, particularly in the context of V(D)J recombination. In this episode, they discuss the challenges of quantifying diversity within the immune repertoire and provide an overview of the powerful software tools developed by their group.

Listen now via your favorite podcast platform or here: http://onairr.airr-community.org. New episodes will be released monthly.

2025 Antibody Research Competition – Now Open!

by


We are happy to announce that the 2025 Antibody Society Research Competition is officially open to student and postdoctoral members of The Antibody Society. This competition is designed to recognize and support the innovative research contributions of early-career scientists in the field of antibody science.

Competition Details:

We invite students and postdocs to submit a summary of their research on any topic related to antibody science. While traditional poster presentations are welcome, we also encourage creative formats, such as videos or other unique presentations.

Relevant Topics Include

  • Antibody Engineering/Design
  • Antibody Therapeutics
  • Fc Effector Functions
  • Bispecific Antibodies
  • Antibody-Drug Conjugates
  • Adaptive Immune Receptor Repertoires

Prizes for Winners:

Two winners (1 student and 1 postdoc) will be selected based on originality, creativity, scientific merit, and clarity. Each winner will receive:

  • A $400 cash prize
  • Free registration for either:
    • Schrödinger’s online course,
    • Introduction to Computational Antibody Engineering OR
    • Virtual Antibody Engineering & Therapeutics

Submission Guidelines:

  • Open only to student and postdoc members of The Antibody Society
  • Submissions must be your own work, but collaborative research is allowed with permission from co-authors
  • Submissions may include unpublished work or content from papers published within the past six months (with proper copyright permissions)
  • By entering the competition, winners agree to have their work published on The Antibody Society’s website

Important Dates:

  • Start Date: February 1, 2025
  • Submission Deadline: April 15, 2025

Please note that only the first 30 submissions will be considered, so we encourage you to submit early. If you’re not yet a member of The Antibody Society, membership is free for students and postdocs, so take this opportunity to join and participate.

To submit your entry or for more information, please email membership@antibodysociety.org.

We look forward to your participation!

FDA approves antibody-drug conjugate Datroway

by

On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC1+ or IHC2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. The recommended datopotamab deruxtecan-dlnk dose is 6 mg/kg (maximum of 540 mg for patients ≥90 kg), administered as an intravenous infusion, once every 3 weeks (21-day cycle), until disease progression or unacceptable toxicity.

Datopotamab deruxtecan is an anti- trophoblast cell-surface antigen 2 (TROP2) ADC in development as a treatment for breast and lung cancer. The payload, a topoisomerase I inhibitor, is conjugated to a humanized IgG1k antibody via a cleavable linker. Daiichi Sankyo maintains exclusive rights for this ADC in Japan but has an agreement with AstraZeneca to jointly develop and commercialize datopotamab deruxtecan in the rest of the world. DATROWAY® was first approved in December 2024 in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy.

Efficacy was evaluated in TROPION-Breast01 (NCT05104866), a multicenter, open-label, randomized trial.  A total of 732 patients were randomized (1:1) to datopotamab deruxtecan (n=365) or investigator’s choice of chemotherapy (n=367); eribulin (60%), capecitabine (21%), vinorelbine (10%), or gemcitabine (9%). The major efficacy outcome measures were progression-free survival (PFS), assessed by blinded independent central review (BICR), based on RECIST v1.1 and overall survival (OS). Additional efficacy outcomes included confirmed objective response rate (ORR) and duration of response (DOR) by BICR. Median PFS was 6.9 months (95% CI: 5.7, 7.4) in the datopotamab deruxtecan-dlnk arm and 4.9 months (95% CI: 4.2, 5.5) in the chemotherapy arm (Hazard ratio 0.63 [95% CI: 0.52, 0.76] two-sided p-value <0.0001). Median OS was 18.6 months (95% CI: 17.3, 20.1) in the datopotamab deruxtecan-dlnk arm and 18.3 months (95% CI: 17.3, 20.5) in the chemotherapy arm (Hazard ratio 1.01 [95% CI: 0.83, 1.22]; two-sided p-value was not statistically significant). Confirmed ORR was 36% (95% CI: 31, 42) and 23% (95% CI: 19, 28) and median DOR was 6.7 months (95% CI: 5.6, 9.8) and 5.7 months (95% CI: 4.9, 6.8) in the datopotamab deruxtecan-dlnk and chemotherapy arms, respectively.

Curious about what other antibody therapeutics are approved or in regulatory review? Our online table contains details for over 200 such antibodies!

Register now for the Jan 30th AIRR Community Seminar Series

by

Register now for the January 30th AIRR Community Seminar Series

Registration for the January 30th (4:00 PM – 5:30 PM CET) AIRR-C Seminar Series session is open. Following the usual format of the series, an established and an early career scientist will discuss their AIRR-seq related research.

Mikhail Pogorelyy of St. Jude Children’s Research Hospital, USA will present “TIRTL-seq: Deep, quantitative, and affordable paired TCR repertoire sequencing.” Next, Eglantine Hector of the Marseille Immunology Center, France will present “SeQuoIA: a pipeline for inference of phylogeny and selection pressure in BCR sequences from integrative single-cell sequencing data.”

REGISTER NOW!

Visit the AIRR Community Seminar Series website to learn more about this monthly series and access the recordings of past sessions.